CA-ENERGY-VAULT/HELENA
20.7.2021 14:02:41 CEST | Business Wire | Press release
Global problem-solving organization Helena and Energy Vault , the creator of renewable energy storage products that are transforming the world’s approach to utility-scale energy storage for grid resiliency, today announced a strategic partnership to identify additional opportunities for Energy Vault’s breakthrough waste remediation technologies as the company begins deployment of its innovative energy storage system worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210720005330/en/
While supporting Energy Vault’s expansion through Helena’s vast network, the strategic partnership will focus on accelerating adoption by global energy providers of the company’s transformative technology, in particular its advanced material remediation innovations. The unique application of material science to the main energy storage medium – the composite blocks – enables the use of alternative materials to replace environmentally unfriendly substances like concrete, which accounts for 7-8% of greenhouse gas emissions. In addition, the technology can accommodate the recycling of various pre-existing waste materials, which in return helps large utility and industrial companies transform financial and environmental liabilities into infrastructure assets to support their transition to a fully circular economic approach. For example, coal ash waste and retired wind turbine blades can be re-directed from landfills into its custom-made composite blocks that anchor the company’s gravity-powered systems. By maximizing the use of locally sourced soil, sand and waste materials, including outputs from fossil fuel production, Energy Vault’s supply chain design reduces the impact of GHGs from the transport sector while increasing jobs for local economies, the end result being an end-of-life solution for materials that are difficult to break down and can have negative environmental consequences. This beneficial reuse eliminates waste and enables the continual use of local resources within the framework of a circular economy.
This work will build upon the technology and commercial partnership that it previously announced in 2019 with CEMEX Research Group, a subsidiary of global building materials company CEMEX, and supports the collaboration Energy Vault most recently announced earlier this month with leading global energy powerhouse Enel Green Power.
As part of the partnership, which began in late 2020, Helena also announced that it completed a $20 million investment in Energy Vault. Helena’s investment and partnership with Energy Vault is conducted through Helena’s for-profit arm, Helena Special Investments, which operates projects that implement solutions to societal problems through for-profit means. Helena has joined other investors including Saudi Aramco Energy Ventures, SoftBank Vision Fund, CEMEX Ventures, Idealab, and Neotribe Ventures. As part of its investment, Helena Founder and CEO Henry Elkus joined Energy Vault’s board of directors.
"Our job at Helena is to identify and implement solutions to the critical global problems of the next 50 years. It doesn’t get much more critical than radically improving energy storage. It is both a short-term solution to the problems we have seen recently in areas like Texas and a long-term necessity for the world to sustainably transition away from fossil fuels. We believe Energy Vault will play a fundamental role in furthering that transition,” said Helena Founder and CEO Henry Elkus. “We are also supporting Energy Vault’s strategy in addressing another essential problem – remediating waste. The company’s ability to use massive quantities of waste material to construct its systems only makes the impact more real and the business case more viable while also providing utilities a streamlined method to transition out of fossil fuel-based energy production and recycle legacy assets.”
“We are thrilled to partner with Helena in pursuit of our shared mission and mutual passion in accelerating the decarbonization of our planet,” said Robert Piconi, CEO and Co-Founder, Energy Vault. “Given Helena’s focus in taking on the most significant global challenges – in this case the global transition to clean energy production – we are grateful to have them alongside us as both strategic partner and investor. Helena and its global network are already making an impact toward our technology adoption, and our continued work together will help the world to take a vital step towards combating the negative impacts of climate change.”
About Helena
Helena is a global problem-solving organization. Through Helena Projects , Helena seeks to implement solutions to critical societal problems. Since its founding in 2015, Helena Projects have included: America In One Room, which garnered the attention of President Barack Obama and The New York Times for one of the most significant political experiments in U.S. history; Factory in the Sky, which supported the development and construction of the world’s first carbon capture factory; Shield, which worked to protect the electrical grid from foreign and domestic threats; and most recently The Covid Project, which supplied tens of millions units of medical supplies and personal protective equipment to frontline responders during the COVID-19 pandemic. To learn more about Helena, visit helena.org .
About Energy Vault
Energy Vault is the creator of renewable energy storage products that are transforming the world’s approach to utility-scale energy storage for grid resiliency. Applying conventional physics fundamentals of gravity and potential energy, the system combines an innovative crane design that lifts specially designed, massive composite blocks with a proprietary, cloud-based software platform which orchestrates the storage and discharge of electricity. Utilizing 100% eco-friendly materials at unprecedented economics, Energy Vault is accelerating the shift to a fully renewable world.
For more information about Energy Vault, please visit energyvault.com and @EnergyVaultInc .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210720005330/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom